24 completed, 4 recruiting, 4 terminated, 4 unknown. 38 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Completed 24, Recruiting 4, Terminated 4, Unknown 4, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1104 | 2026-09-25 | 2026-10-23 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-08-27 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO Tabirafusp tedromer, Aflibercept (2.0 mg) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Kodiak Sciences Inc | 910 | 2026-08-03 | 2026-08-21 |
| A Study to Compare GNR-139 and Eylea® in Patients With nAMD aflibercept, Eylea - nAMD | Phase 3 | Recruiting | AO GENERIUM | 180 | 2026-07-22 | 2026-09-30 |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Active not recruiting | Kodiak Sciences Inc | 675 | 2024-08-23 | 2026-04-29 |
| Efficacy and Safety of RC28-E Versus Aflibercept RC28-E, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | RemeGen Co., Ltd. | 432 | 2023-03-14 | 2023-08-31 |
| Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema CT-P42, Eylea - Diabetic Macular Edema (DME) | Phase 3 | Completed | Celltrion | 348 | 2021-07-22 | 2023-12-05 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 729 | 2021-03-02 | 2024-08-06 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Branch Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 553 | 2021-03-02 | 2024-08-06 |
| Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macula Edema | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2021-02-01 | 2021-03-04 | |
| A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） LY09004, Eylea - Age Related Macular Degeneration | Phase 3 | Unknown | Luye Pharma Group Ltd. | 416 | 2020-11-01 | 2020-10-01 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 459 | 2020-09-30 | 2024-08-22 |
| A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 460 | 2020-09-30 | 2024-08-22 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) KSI-301, Aflibercept, Sham Procedure - Macular Edema, Retinal Vein Occlusion | Phase 3 | Completed | Kodiak Sciences Inc | 568 | 2020-09-25 | 2024-06-26 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration Brolucizumab 6mg, Aflibercept 2 mg - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 397 | 2019-11-29 | 2024-12-09 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Brolucizumab 6 mg, Aflibercept 2 mg - Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 734 | 2019-09-25 | 2024-10-09 |
| To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 266 | 2019-08-23 | 2024-10-09 |
| Treat and Extend Analysis Trial With Aflibercept in Wet-AMD Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | Michel Giunta | 40 | 2019-07-24 | 2022-06-14 |
Showing 20 of 38. Sign in to see all of them.
Macular Edema (10) · Diabetic Retinopathy (8) · Macular Degeneration (8) · Vision Disorders (8) · Eye Diseases (7) · Retinal Degeneration (7) · Retinal Diseases (7) · Wet Macular Degeneration (6) · Vision, Low (5) · Retinal Vein Occlusion (4) · Diabetes Mellitus (2) · Blindness (1) · Choroidal Neovascularization (1) · Geographic Atrophy (1) · Glaucoma (1)
Novartis Pharmaceuticals (8) · Kodiak Sciences Inc (7) · Hoffmann-La Roche (6) · Jaeb Center for Health Research (4) · Merck Sharp & Dohme LLC (2) · AO GENERIUM (1) · Celltrion (1) · Centre Hospitalier Intercommunal Creteil (1) · East Florida Eye Institute (1) · Instituto de Olhos de Goiania (1) · Luye Pharma Group Ltd. (1) · Michel Giunta (1) · Mylan Pharmaceuticals Inc (1) · Ophthalmic Consultants of Long Island (1) · RemeGen Co., Ltd. (1)
United States (27) · Germany (12) · Hungary (12) · Italy (11) · Poland (11) · Spain (11) · France (10) · Czechia (9) · Israel (9) · Russia (9) · Canada (8) · Puerto Rico (8) · Argentina (7) · Australia (7) · China (7)
Pablo Velazquez-Martin, MD (6) · Adam Glassman, MS (1) · Andrew Antoszyk, MD (1) · Carl Baker, MD (1) · Eric Souied, MD (1) · Glenn L Stoller, MD (1) · Ingrid U Scott, M.D., M.P.H. (1) · J. Pablo Velazquez-Martin, MD (1) · Jennifer K. Sun, MD, MPH (1) · Joao J Nassaralla, MD PhD (1) · Ronald E Frenkel, MD (1) · Youxin Chen (1)
PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38758639, PMID 38852921, PMID 40668667, PMID 41534798, PMID 41712218, PMID 42753135, PMID 42771326, PMID 28492910, PMID 30681643, PMID 31037289, PMID 31169862, PMID 31600368, PMID 33320223, PMID 33415354, PMID 33784735, PMID 33956075, PMID 34709363, PMID 35461831, PMID 35833805, PMID 36584835, PMID 36749332, PMID 36912792, PMID 37220815, PMID 37943541, PMID 37955955, PMID 37971723, PMID 37972038, PMID 39264599, PMID 39580145, PMID 40107501, PMID 40496217, PMID 40879891, PMID 41961203, PMID 42005909, PMID 42054088, PMID 42104207, PMID 42373197, PMID 42492647
2017 (4), 2018 (2), 2019 (2), U10EY023521 (1), U10EY023529 (1), U10EY023533 (1)